A Review on the Antiparasitic Drug Ivermectin for Various Viral Infections and Possibilities of Using It for Novel Severe Acute Respiratory Syndrome Coronavirus 2: New Hope to Treat Coronavirus Disease-2019

Jabeen, Talha; Khader, Mohd Abdul; Jabeen, Shayestha

doi:10.22159/ajpcr.2020.v13i8.38357

Cited by 5 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies that examined the efficacy of Ivermectin have shown antiviral activity for many viral infections (Jabeen et al, 2020). A retrospective analysis of consecutive patients with COVID-19 from four hospitals in Florida, USA, compared 173 patients who received Ivermectin plus Hydroxychloroquine, or Hydroxychloroquine with Azithromycin, versus 103 patients who received usual care plus Hydroxychloroquine, or Hydroxychloroquine with Azithromycin.…”

Section: Type Of Treatmentmentioning

confidence: 99%

Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico

Lima-Morales¹,

Méndez‐Hernández²,

Flores³

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Objective There is an urgent need for effective treatments to prevent or attenuate lung and systemic inflammation, endotheliitis, and thrombosis related to COVID-19. The aim of this study was to assess the effectiveness of a multidrug-therapy consisting of Ivermectin, Azithromycin, Montelukast and Acetylsalicylic Acid (“TNR4” therapy) to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. Design and Methods A comparative effectiveness study was performed among 768 confirmed SARS-CoV-2 cases aged 18 to 80 years, who received ambulatory care at the Ministry of Health of Tlaxcala. A total of 481 cases received the TNR4 therapy, while 287 received another treatment (comparison group). All participants received home visits and/or phone calls for clinical evaluation during the 14 days after enrollment. Results Nearly 85% of cases who received the TNR4 recovered within 14 days compared to 59% in the comparison group. Likelihood of recovery within 14 days was 3.4 times greater among the TNR4 group than in the comparison group. Patients treated with TNR4 had a 75% and 81% lower risk of being hospitalized or death, respectively, than the comparison group. Conclusions TNR4 therapy improved recovery and prevented risk of hospitalization and death among ambulatory COVID-19 cases.

show abstract

Section: Type Of Treatmentmentioning

confidence: 99%

Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico

Lima-Morales¹,

Méndez‐Hernández²,

Flores³

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…An in vitro study reported that ivermectin inhibits SARS-CoV-2, with a single addition to Vero/hSLAM cells 2-h post infection and reduces viral RNA ~5000- at 48 h. 2 , 3 , 10 , 11 , 26 , 27 Recent studies that examined the efficacy of ivermectin have shown antiviral activity for many viral infections. 28 …”

Section: Discussionmentioning

confidence: 99%

Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19

Aref¹,

Bazeed²,

Hassan³

et al. 2021

IJN

View full text Add to dashboard Cite

Background Ivermectin is an FDA-approved broad-spectrum anti-parasitic agent that has been shown to inhibit SARS-CoV-2 replication in vitro . Objective We aimed to assess the therapeutic efficacy of ivermectin mucoadhesive nanosuspension intranasal spray in treatment of patients with mild COVID-19. Methods This clinical trial included 114 patients diagnosed as mild COVID-19. Patients were divided randomly into two age and sex-matched groups; group A comprising 57 patients received ivermectin nanosuspension nasal spray twice daily plus the Egyptian protocol of treatment for mild COVID-19 and group B comprising 57 patients received the Egyptian protocol for mild COVID-19 only. Evaluation of the patients was performed depending on improvement of presenting manifestations, negativity of two consecutive pharyngeal swabs for the COVID-19 nucleic acid via rRT-PCR and assessments of hematological and biochemical parameters in the form of complete blood counts, C-reactive protein, serum ferritin and d-dimer which were performed at presentation and 7 days later. Results Of the included patients confirmed with mild COVID-19, 82 were males (71.9%) and 32 females (28.1%) with mean age 45.1 ± 18.9. In group A, 54 patients (94.7%) achieved 2 consecutive negative PCR nasopharyngeal swabs in comparison to 43 patients (75.4%) in group B with P = 0.004. The durations of fever, cough, dyspnea and anosmia were significantly shorter in group A than group B, without significant difference regarding the duration of gastrointestinal symptoms. Duration taken for nasopharyngeal swab to be negative was significantly shorter in group A than in group B (8.3± 2.8 days versus 12.9 ± 4.3 days; P = 0.0001). Conclusion Local use of ivermectin mucoadhesive nanosuspension nasal spray is safe and effective in treatment of patients with mild COVID-19 with rapid viral clearance and shortening the anosmia duration. Clinicaltrials.gov Identifier NCT04716569; https://clinicaltrials.gov/ct2/show/NCT04716569 .

show abstract

“…In present scenario, this drug is also useful in the management of SARS-COV-2. 9,10 The available literature studies describe utilization of few analytical methods for the evaluation of ivermectin in tablet dosage form. These methods are based on various techniques such as Ultra Violet spectroscopy, diffused reflectance spectroscopy, HPTLC, HPLC with Tandem mass spectroscopy and RP-HPLC.…”

Section: Introductionmentioning

confidence: 99%

Analytical Method Development And Validation Parameters Of Drug Ivermectin

goswami

Nagarajan

Goel

et al. 2022

Int J Life Sci Pharm Res

View full text Add to dashboard Cite

An accurate, easy, detailed, selective and fast RP-HPLC stability representative technique was developed and validated for assessment of ivermectin in tablet dosage form. The Reverse Phase High Performance Liquid Chromatographic technique was developed for routine quantification of ivermectin in laboratory prepared mixtures as well as in combined dosage forms. The chromatographic separation was accomplished with INERTSIL C-18 ODS 250×4.6mm, 5µm particle size column along with acetonitrile and methanol as the mobile phase at a flow rate of 1ml/min. Quantification was completed by using a UV detector at 245 nm and the run time was 10 minutes. The retention time was found to be 4.198 min for ivermectin. The linearity was observed in the range of 1-32µg/ml with correlation coefficient r= 0.9798. The % RSD for intraday and interday precision was 1.352 and 1.589 respectively. The LOD and LOQ values were found to be 2.93 and 8.79, respectively. The system suitability parameters for ivermectin such as theoretical plates and tailing factor were found to be 129.949 and 2.0, respectively. Robustness was also studied and there was no significant variation in the system suitability of the analytical method by incorporating small changes in experimental parameters. The technique has been validated for linearity, precision, accuracy and other parameters as approved by ICH guidelines. The results obtained by RP- HPLC methods are found to be fast, detailed, selective and accurate. Therefore, proposed analytical method can be used for regular analysis of ivermectin in injection, tablet and other formulations.

show abstract

A Review on the Antiparasitic Drug Ivermectin for Various Viral Infections and Possibilities of Using It for Novel Severe Acute Respiratory Syndrome Coronavirus 2: New Hope to Treat Coronavirus Disease-2019

Cited by 5 publications

References 22 publications

Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico

Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico

Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19

Analytical Method Development And Validation Parameters Of Drug Ivermectin

Contact Info

Product

Resources

About